Progression of immunotherapy in gastric cancer / 中华胃肠外科杂志
Chinese Journal of Gastrointestinal Surgery
;
(12): 225-232, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-341552
ABSTRACT
Gastric cancer is a malignant disease with high incidence and mortality. The therapeutic methods for advanced gastric cancer, including chemotherapy and targeted therapy are very limited. Immunotherapy is a new method for cancer treatment. The immune checkpoint inhibitors developed for cancer treatment mainly target the CTLA-4 and PD-1/PD-L pathways. There have already been several inhibitors approved for the treatment of melanoma and non-small cell lung cancer by the FDA, including Ipilimumab (fully human antibody against CTLA-4), Pembrolizumab (fully human antibody against PD-1) and Nivolumab (fully human antibody against PD-1). There are also many on-going clinical trials investigating the value of immune checkpoint inhibitors in treating various malignancies, including advanced gastric cancer. In KEYNOTE-012 trial, for advanced gastric and esophagogastric junction cancer anti-PD-1 therapy seemed to be safe and effective for advanced gastric cancer with PD-L1 positivity. Moreover, studies of adoptive cell therapy and tumor vaccine in gastric cancer are underway. Here the latest developments in immunotherapy for gastric cancer will be illustrated.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Stomach Neoplasms
/
Therapeutics
/
Disease Progression
/
Therapeutic Uses
/
Antibodies, Monoclonal, Humanized
/
B7-H1 Antigen
/
CTLA-4 Antigen
/
Programmed Cell Death 1 Receptor
/
Ipilimumab
/
Immunotherapy
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Gastrointestinal Surgery
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS